![](/img/cover-not-exists.png)
Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
Kristeleit, R.S., Shapira-Frommer, R., Oaknin, A., Balmaña, J., Ray-Coquard, I.L., Domchek, S., Tinker, A.V., Castro, C.M., Welch, S., Poveda, A.M., Bell-Mcguinn, K., Konecny, G., Giordano, H., MaloneVolume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw374.03
Date:
October, 2016
File:
PDF, 41 KB
english, 2016